Jane Street’s AbbVie ABBV Stock Holding History

Jane Street’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$222M	Buy	1,019,000 +185,100	+22%	+$41.1M	0.03%	367
2025 Q4	$191M	Sell	833,900 -1,011,800	-55%	-$230M	0.03%	373
2025 Q3	$427M	Buy	1,845,700 +581,600	+46%	+$118M	0.07%	197
2025 Q2	$235M	Buy	1,264,100 +54,800	+5%	+$10.2M	0.05%	250
2025 Q1	$253M	Buy	1,209,300 +206,800	+21%	+$40.2M	0.06%	181
2024 Q4	$178M	Sell	1,002,500 -285,700	-22%	-$52.5M	0.04%	274
2024 Q3	$254M	Sell	1,288,200 -230,400	-15%	-$43M	0.06%	180
2024 Q2	$260M	Buy	1,518,600 +231,400	+18%	+$38.3M	0.06%	171
2024 Q1	$234M	Sell	1,287,200 -4,900	-0.4%	-$844K	0.05%	195
2023 Q4	$200M	Buy	1,292,100 +480,100	+59%	+$70M	0.05%	224
2023 Q3	$121M	Buy	812,000 +196,200	+32%	+$28.8M	0.04%	274
2023 Q2	$83M	Sell	615,800 -3,700	-0.6%	-$543K	0.03%	401
2023 Q1	$98.7M	Sell	619,500 -394,000	-39%	-$60.2M	0.04%	305
2022 Q4	$164M	Buy	1,013,500 +149,800	+17%	+$23M	0.08%	177
2022 Q3	$116M	Sell	863,700 -469,800	-35%	-$67.4M	0.05%	236
2022 Q2	$204M	Sell	1,333,500 -119,000	-8%	-$18.2M	0.09%	148
2022 Q1	$235M	Sell	1,452,500 -791,400	-35%	-$115M	0.08%	160
2021 Q4	$304M	Buy	2,243,900 +1,620,600	+260%	+$191M	0.1%	116
2021 Q3	$67.2M	Sell	623,300 -266,800	-30%	-$30.5M	0.02%	477
2021 Q2	$100M	Buy	890,100 +256,000	+40%	+$28.8M	0.04%	312
2021 Q1	$68.6M	Sell	634,100 -292,200	-32%	-$31.3M	0.03%	381
2020 Q4	$99.3M	Sell	926,300 -8,800	-0.9%	-$846K	0.05%	247
2020 Q3	$81.9M	Sell	935,100 -93,500	-9%	-$8.8M	0.05%	269
2020 Q2	$101M	Buy	1,028,600 +94,000	+10%	+$8.28M	0.08%	183
2020 Q1	$71.2M	Buy	934,600 +2,700	+0.3%	+$230K	0.07%	181
2019 Q4	$82.5M	Buy	931,900 +57,000	+7%	+$4.73M	0.12%	115
2019 Q3	$66.2M	Buy	874,900 +184,800	+27%	+$12.7M	0.11%	132
2019 Q2	$50.2M	Buy	690,100 +497,400	+258%	+$39.1M	0.09%	166
2019 Q1	$15.5M	Sell	192,700 -31,700	-14%	-$2.59M	0.03%	501
2018 Q4	$20.7M	Buy	224,400 +55,000	+32%	+$4.84M	0.04%	313
2018 Q3	$16M	Buy	169,400 +61,100	+56%	+$5.79M	0.03%	399
2018 Q2	$10M	Sell	108,300 -213,100	-66%	-$20.8M	0.02%	610
2018 Q1	$30.4M	Buy	321,400 +180,500	+128%	+$19.8M	0.08%	188
2017 Q4	$13.6M	Sell	140,900 -48,400	-26%	-$4.56M	0.04%	404
2017 Q3	$16.8M	Buy	189,300 +141,200	+294%	+$10.7M	0.05%	316
2017 Q2	$3.49M	Buy	48,100 +38,700	+412%	+$2.6M	0.01%	1020
2017 Q1	$613K	Sell	9,400 -175,000	-95%	-$11M	﹤0.01%	2641
2016 Q4	$11.5M	Buy	184,400 +178,000	+2,781%	+$10.9M	0.05%	304
2016 Q3	$404K	Sell	6,400 -103,700	-94%	-$6.71M	﹤0.01%	2989
2016 Q2	$6.82M	Buy	110,100 +36,000	+49%	+$2.19M	0.03%	489
2016 Q1	$4.23M	Buy	74,100 +30,600	+70%	+$1.71M	0.02%	648
2015 Q4	$2.58M	Buy	43,500 +200	+0.5%	+$11.5K	0.02%	864
2015 Q3	$2.36M	Buy	43,300 +39,300	+983%	+$2.56M	0.01%	845
2015 Q2	$269K	Sell	4,000 -12,100	-75%	-$790K	﹤0.01%	2938
2015 Q1	$942K	Buy	+16,100	New	+$973K	0.01%	1423

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jane Street's ABBV Position: Q1 2026 in Review

Jane Street reduced its AbbVie (ABBV) stake by 14% in Q1 2026, selling an estimated $2.75M and leaving 77,362 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

Jane Street first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $107M in Q2 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Jane Street held 77,362 shares of AbbVie worth $16.8M as of Q1 2026.
Jane Street sold 12,385 AbbVie shares in Q1 2026, an estimated $2.75M.
AbbVie made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1952 holding.
Jane Street first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
Jane Street's AbbVie position peaked at $107M in Q2 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.